NEW YORK (GenomeWeb) – Israeli molecular diagnostics firm Pronto Diagnostics recently said that it has combined its suite of genetic tests with FDNA's Face2Gene phenotyping applications.
Pronto offers both next-generation sequencing-based gene panels and exome testing as well as single-gene molecular tests.
FDNA's Face2Gene technology uses facial analysis, deep learning, and artificial intelligence to improve molecular diagnostics. It enables clinicians to integrate phenotypic data into genetic testing pipelines in order to improve the chances of making a diagnosis.
"As a deep learning platform, Face2Gene grows in capabilities and disease understanding with increased use," FDNA CEO Dekel Gelbman said in a statement.
Pronto CEO Nir Navot added that the firm is "dedicated to bringing patients answers to complex health questions, and this new technology will bring about those answers more effectively and efficiently."